221 completed, 43 terminated, 43 unknown, 21 recruiting. 113 Phase 3, 102 Phase 2, 84 Phase 4, 37 Phase 1, 25 Not applicable.
Follow Zoledronic Acid: new trials by email Literature Review of Zoledronic Acid trials Research Report on Zoledronic Acid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sequential Treatment With Romosozumab Followed by Denosumab vs. Zoledronic Acid for Gains in HIP BMD Romosozumab, Zoledronic Acid 5 MG in 5 ML Injection, Calcium 500 mg and Vitamin D3 800 IU - Osteoporosis in Post-menopausal Women | Phase 4 | Not yet recruiting | Sahlgrenska University Hospital | 216 | 2027-01-11 | 2026-08-19 |
| RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients Denosumab (Prolia), Zoledronic acide (Aclasta) - Sarcopenia in Elderly | Phase 3 | Not yet recruiting | Prince of Wales Hospital, Shatin, Hong Kong | 130 | 2027-01-01 | 2026-09-16 |
| EFFICACY AND SAFETY OF ZOLEDRONATE VERSUS PLACEBO ON PAIN AT WEEK 12 IN PEDIATRIC PATIENTS WITH CHRONIC RECURRENT MULTIFOCAL OSTEOMYELITIS Zoledronic Acid / Zoledronate 4 MG/100 ML Intravenous Solution, NaCL 0.9% Intravenous Solution - Osteomyelitis Chronic | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 30 | 2026-09-15 | 2026-06-25 |
| Pharmacokinetics of Zoledronic Acid in Patients on Dialysis Zoledronic Acid Injection, 5.0 mg, single dose, Zoledronic Acid Injection, 2.5 mg, single dose - Chronic Kidney Disease, Osteoporosis | Phase 1 | Not yet recruiting | University of Campinas, Brazil | 24 | 2026-08-15 | 2026-09-10 |
| Zoledronate to Prevent Bone Health Complications in Pediatric Hematopoietic Stem Cell Transplant Survivors Zoledronate - Hematopoietic Stem Cell Transplantation | Phase 1 | Recruiting | Children's Hospital Medical Center, Cincinnati | 20 | 2026-07-17 | 2026-08-10 |
| Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases Zanzalintinib, Investigator Choice of Bone Strengthening Agents (BSA), Non-Investigational Radiation Therapy (RT) - Clear Cell Renal Cell Cancer (ccRCC), Clear Cell Renal Carcinoma | Phase 2 | Recruiting | Kelly Fitzgerald, MD | 20 | 2026-06-10 | 2026-07-27 |
| Zoledronic Acid Treatment in Patients With Congenital Dyserythropoietic Anemia zoledronic acid - Congenital Dyserythropoietic Anemia (CDA) | Phase 1 / Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 2 | 2026-02-25 | 2026-03-13 |
| Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors Miltenyi CliniMACS Prodigy ® system, Zoledronic acid - Neuroblastoma, Rhabdomyosarcoma | Phase 1 / Phase 2 | Recruiting | University of Florida | 27 | 2026-02-11 | 2026-06-30 |
| Step-down Therapy After Long-term Osteoporosis Treatment zoledronate, Denosumab De-escalation - Osteoporosis | Phase 4 | Recruiting | National Taiwan University Hospital | 44 | 2026-01-01 | 2025-12-15 |
| Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea Romosozumab, Placebo, Zoledronic acid - FHA (Functional Hypothalamic Amenorrhea) | Phase 3 | Recruiting | Massachusetts General Hospital | 114 | 2025-03-19 | 2026-04-23 |
| Zoledronic Acid Combined With EC-T for Triple-Negative Breast Cancer Zoledronic Acid Combined with Neoadjuvant Chemotherapy (EC-T) - Breast Cancer Metastatic | Not applicable | Active not recruiting | Xijing Hospital | 99 | 2025-03-10 | 2025-07-29 |
| Bisphosphonate Prior to Parathyroidectomy in Primary Hyperparathyroidism Zoledronic acid 4 mg, Natriumklorid 9 mg/ml, Fresenius Kabi - Primary Hyperparathyroidism | Phase 4 | Recruiting | University of Aarhus | 140 | 2025-03-01 | 2026-10-01 |
| Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis Zumsemetinib, Capecitabine, Zoledronic acid - Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer | Phase 1 / Phase 2 | Recruiting | Washington University School of Medicine | 152 | 2025-01-30 | 2026-10-13 |
| Zoledronic Acid for the Prevention of TDF-sparing ART-induced Bone Mass Density Loss in Treatment-naive HIV Positive Individuals Zoledronic Acid 5 mg/Bag 100 ml Inj - HIV Infected Individuals, Osteopenia | Phase 4 | Recruiting | Hadassah Medical Organization | 110 | 2024-12-09 | 2025-09-18 |
| ETC-159 In Combination With Pembrolizumab In Advanced MSS/pMMR Ovarian Cancers ETC-159, Pembrolizumab, Denosumab / Zoledronic Acid - With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer | Phase 1 | Recruiting | National University Hospital, Singapore | 16 | 2024-12-09 | 2025-07-25 |
| Effect of Local Subperiosteal Zoledronic Acid Injection on the Survival of Orthodontic Miniscrews Zoledronic Acid, Normal saline (0.9% sodium chloride) - Orthodontic Appliance Complication | Not applicable | Completed | Latakia University | 68 | 2024-12-01 | 2026-04-22 |
| Intraperitoneal Immune Checkpoint Inhibitors and Zoledronic Acids for Gastric Cancer Malignant Ascites zoledronic acid plus Sintilimab intraperitoneal injection - Cancer of Stomach, Adenocarcinoma, Ascites, Malignant | Phase 1 / Phase 2 | Recruiting | Qilu Hospital of Shandong University | 24 | 2024-09-12 | 2025-11-19 |
| A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Compared to Zoledronic Acid JMT103, zoledronic acid - Imaging Examination Shows at Least One Site With Bone Metastases From Soild Tumors | Phase 3 | Not yet recruiting | Shanghai JMT-Bio Inc. | 1360 | 2024-04-05 | 2024-01-24 |
| Preserving Geriatric Muscle With an Osteoporosis Medication Denosumab 60 MG/ML, Zoledronic Acid 5Mg/Bag 100Ml Infusion - Osteoporosis | Phase 4 | Recruiting | Chrissy Kistler | 155 | 2024-02-08 | 2026-09-23 |
| Efficacy of a Herbal Formula for Bone Metastases 4 Herbs Formula - Bone Metastases | Phase 1 / Phase 2 | Unknown | Chinese University of Hong Kong | 36 | 2024-02-01 | 2023-09-07 |
Showing 20 of 355. Sign in to see all of them.
Osteoporosis (78) · Breast Neoplasms (71) · Prostatic Neoplasms (50) · Bone Diseases, Metabolic (33) · Multiple Myeloma (30) · Neoplasm Metastasis (28) · Osteoporosis, Postmenopausal (18) · Pain (16) · Fractures, Bone (12) · Carcinoma, Non-Small-Cell Lung (11) · Neoplasms (10) · Lung Neoplasms (8) · Neoplasms, Plasma Cell (7) · Osteosarcoma (7) · Bone Diseases (6)
Novartis Pharmaceuticals (59) · Novartis (19) · Amgen (8) · Massachusetts General Hospital (7) · Alliance for Clinical Trials in Oncology (5) · Washington University School of Medicine (5) · M.D. Anderson Cancer Center (4) · Ottawa Hospital Research Institute (4) · University of Wisconsin, Madison (4) · 424 General Military Hospital (3) · Fudan University (3) · Hoffmann-La Roche (3) · Mayo Clinic (3) · Nantes University Hospital (3) · National Taiwan University Hospital (3)
United States (142) · Canada (37) · Germany (34) · China (28) · Australia (27) · United Kingdom (25) · France (24) · Italy (18) · Spain (16) · Belgium (14) · Denmark (12) · Greece (12) · South Korea (12) · Hungary (11) · New Zealand (9)
Dawn Hershman, MD (3) · Susan L Greenspan, MD (3) · Alberto Zambelli, MD (2) · Mark Clemons, MD (2) · Nicholas D. James, MD (2) · Robert E. Coleman, MD, FRCP (2) · Shi-Ming Tu, MD (2) · Stephanie Hines, MD (2) · Thomas J Schnitzer, MD, PhD (2) · Willem Lems, Prof (2) · A H Taminiau, MD PhD (1)
PMID 38979716, PMID 33270906, PMID 21037195, PMID 22975218, PMID 23975226, PMID 26093811, PMID 31401903, PMID 40446745, PMID 19362675, PMID 24590644, PMID 25976743, PMID 26335402, PMID 27400896, PMID 35309986, PMID 36919608, PMID 14742657, PMID 15860850, PMID 16018754, PMID 16224404, PMID 16365178, PMID 16490909, PMID 16637733, PMID 17227801, PMID 17355365, PMID 17476007, PMID 17878149, PMID 18086795, PMID 18404382, PMID 18669874, PMID 18711172, PMID 18777528, PMID 18843680, PMID 18990168, PMID 19017549, PMID 19143027, PMID 19214743, PMID 19287884, PMID 19380451, PMID 19407319, PMID 19455472, PMID 19484483, PMID 19493585, PMID 19507458, PMID 19567517, PMID 20022990, PMID 20079640, PMID 20152674, PMID 20168099, PMID 20234364, PMID 20303574
2008 (6), 2016 (3), P30CA015083 (3), 2004 (2), 2005 (2), 2009 (2), 2017 (2), 2023 (2), U10CA031946 (2), 2014 (1), 2015 (1), 2019 (1), N01CM17104 (1), P01CA081403 (1), P30AG024827 (1)